Reconstitution of TGF-β sensitivity in the VACO-411 human colon carcinoma line by somatic cell fusion with MCF-7

June L. Traicoff, Sumudra Periyasamy, Michael G. Brattain, William Grady, Graham Casey

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We characterized the mechanism of transforming growth factor beta (TGF-β) resistance in the VACO-411 human colon carcinoma line. VACO-411 is unique for several reasons, including having a novel mutator phenotype and wild-type p53. Like many colon tumors, VACO-411 is not growth inhibited by TGF-β. However, VACO-411 represents a subset of colon tumors that are resistant to TGF-β-mediated growth inhibition, despite the expression of functional TGF-β receptors. VACO-411 expresses cell surface TGF-β receptor types I and II, and the coding regions of these receptors are wild type. To further characterize the nature of the VACO-411 defect, we fused VACO-411 with the human breast carcinoma line MCF-7. MCF-7 is also resistant to TGF-β-mediated growth inhibition. However, unlike VACO-411, MCF-7 lacks cell surface expression of TGF-β receptor type II, but does contain an intact postreceptor signaling pathway, as shown by regeneration of TGF-β sensitivity following wild-type TGF-β receptor type II transfection. In contrast to parental VACO-411 and MCF-7, the morphologically distinct cell hybrids were growth inhibited by TGF-β. Therefore, the TGF-β defect in VACO-411 is a postreceptor, loss-of-function mutation which can be genetically complemented. The data suggest that the VACO-411 defect in TGF-β signaling will be able to be further complemented by microcell-mediated chromosome transfer.

Original languageEnglish (US)
Pages (from-to)253-259
Number of pages7
JournalJournal of Biomedical Science
Volume10
Issue number2
DOIs
StatePublished - Mar 20 2003

Fingerprint

Cell Fusion
Transforming Growth Factor beta
Colon
Fusion reactions
Carcinoma
Growth
Defects
Tumors
Transforming Growth Factor beta Receptors
Hybrid Cells
MCF-7 Cells
Chromosomes
Transfection
Regeneration
Neoplasms
Breast Neoplasms
Phenotype
Mutation

Keywords

  • Cell fusions
  • Colon
  • Complementation
  • Signal transduction
  • Transforming growth factor beta

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Reconstitution of TGF-β sensitivity in the VACO-411 human colon carcinoma line by somatic cell fusion with MCF-7. / Traicoff, June L.; Periyasamy, Sumudra; Brattain, Michael G.; Grady, William; Casey, Graham.

In: Journal of Biomedical Science, Vol. 10, No. 2, 20.03.2003, p. 253-259.

Research output: Contribution to journalArticle

Traicoff, June L. ; Periyasamy, Sumudra ; Brattain, Michael G. ; Grady, William ; Casey, Graham. / Reconstitution of TGF-β sensitivity in the VACO-411 human colon carcinoma line by somatic cell fusion with MCF-7. In: Journal of Biomedical Science. 2003 ; Vol. 10, No. 2. pp. 253-259.
@article{e49fdb638f9c47018dbff44ba754c6a8,
title = "Reconstitution of TGF-β sensitivity in the VACO-411 human colon carcinoma line by somatic cell fusion with MCF-7",
abstract = "We characterized the mechanism of transforming growth factor beta (TGF-β) resistance in the VACO-411 human colon carcinoma line. VACO-411 is unique for several reasons, including having a novel mutator phenotype and wild-type p53. Like many colon tumors, VACO-411 is not growth inhibited by TGF-β. However, VACO-411 represents a subset of colon tumors that are resistant to TGF-β-mediated growth inhibition, despite the expression of functional TGF-β receptors. VACO-411 expresses cell surface TGF-β receptor types I and II, and the coding regions of these receptors are wild type. To further characterize the nature of the VACO-411 defect, we fused VACO-411 with the human breast carcinoma line MCF-7. MCF-7 is also resistant to TGF-β-mediated growth inhibition. However, unlike VACO-411, MCF-7 lacks cell surface expression of TGF-β receptor type II, but does contain an intact postreceptor signaling pathway, as shown by regeneration of TGF-β sensitivity following wild-type TGF-β receptor type II transfection. In contrast to parental VACO-411 and MCF-7, the morphologically distinct cell hybrids were growth inhibited by TGF-β. Therefore, the TGF-β defect in VACO-411 is a postreceptor, loss-of-function mutation which can be genetically complemented. The data suggest that the VACO-411 defect in TGF-β signaling will be able to be further complemented by microcell-mediated chromosome transfer.",
keywords = "Cell fusions, Colon, Complementation, Signal transduction, Transforming growth factor beta",
author = "Traicoff, {June L.} and Sumudra Periyasamy and Brattain, {Michael G.} and William Grady and Graham Casey",
year = "2003",
month = "3",
day = "20",
doi = "10.1159/000068706",
language = "English (US)",
volume = "10",
pages = "253--259",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - Reconstitution of TGF-β sensitivity in the VACO-411 human colon carcinoma line by somatic cell fusion with MCF-7

AU - Traicoff, June L.

AU - Periyasamy, Sumudra

AU - Brattain, Michael G.

AU - Grady, William

AU - Casey, Graham

PY - 2003/3/20

Y1 - 2003/3/20

N2 - We characterized the mechanism of transforming growth factor beta (TGF-β) resistance in the VACO-411 human colon carcinoma line. VACO-411 is unique for several reasons, including having a novel mutator phenotype and wild-type p53. Like many colon tumors, VACO-411 is not growth inhibited by TGF-β. However, VACO-411 represents a subset of colon tumors that are resistant to TGF-β-mediated growth inhibition, despite the expression of functional TGF-β receptors. VACO-411 expresses cell surface TGF-β receptor types I and II, and the coding regions of these receptors are wild type. To further characterize the nature of the VACO-411 defect, we fused VACO-411 with the human breast carcinoma line MCF-7. MCF-7 is also resistant to TGF-β-mediated growth inhibition. However, unlike VACO-411, MCF-7 lacks cell surface expression of TGF-β receptor type II, but does contain an intact postreceptor signaling pathway, as shown by regeneration of TGF-β sensitivity following wild-type TGF-β receptor type II transfection. In contrast to parental VACO-411 and MCF-7, the morphologically distinct cell hybrids were growth inhibited by TGF-β. Therefore, the TGF-β defect in VACO-411 is a postreceptor, loss-of-function mutation which can be genetically complemented. The data suggest that the VACO-411 defect in TGF-β signaling will be able to be further complemented by microcell-mediated chromosome transfer.

AB - We characterized the mechanism of transforming growth factor beta (TGF-β) resistance in the VACO-411 human colon carcinoma line. VACO-411 is unique for several reasons, including having a novel mutator phenotype and wild-type p53. Like many colon tumors, VACO-411 is not growth inhibited by TGF-β. However, VACO-411 represents a subset of colon tumors that are resistant to TGF-β-mediated growth inhibition, despite the expression of functional TGF-β receptors. VACO-411 expresses cell surface TGF-β receptor types I and II, and the coding regions of these receptors are wild type. To further characterize the nature of the VACO-411 defect, we fused VACO-411 with the human breast carcinoma line MCF-7. MCF-7 is also resistant to TGF-β-mediated growth inhibition. However, unlike VACO-411, MCF-7 lacks cell surface expression of TGF-β receptor type II, but does contain an intact postreceptor signaling pathway, as shown by regeneration of TGF-β sensitivity following wild-type TGF-β receptor type II transfection. In contrast to parental VACO-411 and MCF-7, the morphologically distinct cell hybrids were growth inhibited by TGF-β. Therefore, the TGF-β defect in VACO-411 is a postreceptor, loss-of-function mutation which can be genetically complemented. The data suggest that the VACO-411 defect in TGF-β signaling will be able to be further complemented by microcell-mediated chromosome transfer.

KW - Cell fusions

KW - Colon

KW - Complementation

KW - Signal transduction

KW - Transforming growth factor beta

UR - http://www.scopus.com/inward/record.url?scp=0037217436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037217436&partnerID=8YFLogxK

U2 - 10.1159/000068706

DO - 10.1159/000068706

M3 - Article

C2 - 12595761

AN - SCOPUS:0037217436

VL - 10

SP - 253

EP - 259

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 2

ER -